David Godwin - PAREXEL International Senior Vice President-Global Business

<div class='logoBackup' style='background:#000000;color: white;font-size:3em;;'>PRX</div>
Mr. David J. Godwin is Senior Vice PresidentGlobal Business Development of the Company. From October 2009 to August 2016, he served as its Corporationrationrate Vice President, CRS of the Company. From October 2008 to October 2009, he served as its Corporationrationrate Vice President, Global Business Development. Prior to this, he held several key marketing, business development and clinical data management positions with the Company
Age: 52  President Since 2016      
781 487-9900  http://www.parexel.com
Godwin holds a BS in Health Information Management from Ithaca College and a Master?s of Business Administration from Boston College.

David Godwin Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 4.71 % which means that it generated profit of $4.71 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 15.1 % meaning that it created $15.1 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Kimberly WhiteVertex Pharmaceuticals Incorpor
Roxanne LaganoZoetis
Charles MilsteinVertex Pharmaceuticals Incorpor
John HendricksonPerrigo Company Plc
Ronald JanishPerrigo Company Plc
Marion McCourtRegeneron Pharmaceuticals
Svend AndersenPerrigo Company Plc
Scott JamisonPerrigo Company Plc
Douglas BoothePerrigo Company Plc
Thomas FarringtonPerrigo Company Plc
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Grainne QuinnPerrigo Company Plc
Joseph LaRosaRegeneron Pharmaceuticals
Umang VohraDr Reddys Laboratories Ltd
Christopher FenimoreRegeneron Pharmaceuticals
Peter PowchikRegeneron Pharmaceuticals
Louis YuPerrigo Company Plc
Jatin ShahPerrigo Company Plc
Cartikeya ReddyDr Reddys Laboratories Ltd
Roman TrawickiZoetis
Paul SilvaVertex Pharmaceuticals Incorpor

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Sold over 100K shares of
3 days ago
Traded for 0.175
Purchased over 10K shares of
3 days ago
Traded for 2.5
Purchased over 100 shares of
3 days ago
Traded for 15.49
Purchased over 100 shares of
few days ago
Traded for 9.2
Purchased over 100 shares of
few days ago
Traded for 54.19
See also Your Equity Center. Please also try CEO Directory module to screen ceos from public companies around the world.